Cargando…

Targeting MET in Non-Small Cell Lung Cancer (NSCLC): A New Old Story?

In recent years, we have seen the development and approval for clinical use of an increasing number of therapeutic agents against actionable oncogenic drivers in metastatic non-small cell lung cancer (NSCLC). Among them, selective inhibitors, including tyrosine kinase inhibitors (TKIs) and monoclona...

Descripción completa

Detalles Bibliográficos
Autores principales:	Spagnolo, Calogera Claudia, Ciappina, Giuliana, Giovannetti, Elisa, Squeri, Andrea, Granata, Barbara, Lazzari, Chiara, Pretelli, Giulia, Pasello, Giulia, Santarpia, Mariacarmela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299133/ https://www.ncbi.nlm.nih.gov/pubmed/37373267 http://dx.doi.org/10.3390/ijms241210119

Ejemplares similares

Overview on Therapeutic Options in Uncommon EGFR Mutant Non-Small Cell Lung Cancer (NSCLC): New Lights for an Unmet Medical Need
por: Pretelli, Giulia, et al.
Publicado: (2023)

Immunotherapy in Early-Stage Non-Small Cell Lung Cancer (NSCLC): Current Evidence and Perspectives
por: Lazzari, Chiara, et al.
Publicado: (2023)

Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to clinical development—a narrative review
por: Santarpia, Mariacarmela, et al.
Publicado: (2023)

Cardiotoxicity Induced by Immune Checkpoint Inhibitors: What a Cardio-Oncology Team Should Know and Do
por: Zito, Concetta, et al.
Publicado: (2022)

Immunotherapeutic Advances for NSCLC
por: Massafra, Marco, et al.
Publicado: (2021)

Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy
por: Santarpia, Mariacarmela, et al.
Publicado: (2017)

Management of Endocrine and Metabolic Toxicities of Immune-Checkpoint Inhibitors: From Clinical Studies to a Real-Life Scenario
por: Spagnolo, Calogera Claudia, et al.
Publicado: (2022)

A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations
por: Santarpia, Mariacarmela, et al.
Publicado: (2021)

Diagnostic-Therapeutic Pathway and Outcomes of Early Stage NSCLC: a Focus on EGFR Testing in the Real-World
por: Pasello, Giulia, et al.
Publicado: (2022)

Mechanisms of resistance to osimertinib
por: Lazzari, Chiara, et al.
Publicado: (2020)

Precision Surgery in NSCLC
por: Cannone, Giorgio, et al.
Publicado: (2023)

Gefitinib Inhibits Invasive Phenotype and Epithelial-Mesenchymal Transition in Drug-Resistant NSCLC Cells with MET Amplification
por: La Monica, Silvia, et al.
Publicado: (2013)

MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells
por: Presutti, Dario, et al.
Publicado: (2015)

Amphiregulin contained in NSCLC-exosomes induces osteoclast differentiation through the activation of EGFR pathway
por: Taverna, Simona, et al.
Publicado: (2017)

Tumor immune microenvironment characterization and response to anti-PD-1 therapy
por: Santarpia, Mariacarmela, et al.
Publicado: (2015)

Canadian Consensus Recommendations on the Management of MET-Altered NSCLC
por: Cheema, Parneet K., et al.
Publicado: (2021)

Neuropsychiatric Adverse Drug Reactions with Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors: An Analysis from the European Spontaneous Adverse Event Reporting System
por: Barbieri, Maria Antonietta, et al.
Publicado: (2023)

Renal Disorders with Oral Tyrosine Kinase Inhibitors in Metastatic Colorectal Cancer: An Analysis from the FDA Adverse Event Reporting System Database
por: Russo, Giulia, et al.
Publicado: (2023)

MET Amplification and Efficacy of Nivolumab in Patients With NSCLC
por: Yoshimura, Katsuhiro, et al.
Publicado: (2021)

Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer?
por: Lazzari, Chiara, et al.
Publicado: (2018)

c-Met as a Target for Personalized Therapy
por: Garajová, Ingrid, et al.
Publicado: (2015)

The old, old story : a novel /
por: Carey, Rosa Nouchette, 1840-1909
Publicado: (1899)

Neuropsychiatric adverse drug reactions with oral tyrosine kinase inhibitors in metastatic colorectal cancer: an analysis from the FDA Adverse Event Reporting System
por: Barbieri, Maria Antonietta, et al.
Publicado: (2023)

Overcoming MET-mediated resistance in oncogene-driven NSCLC
por: Reischmann, Nadine, et al.
Publicado: (2023)

Longitudinal Plasma Proteomics-Derived Biomarkers Predict Response to MET Inhibitors for MET-Dysregulated NSCLC
por: Jie, Guang-Ling, et al.
Publicado: (2023)

An Old Doctor’s Story
Publicado: (1882)

Companion Diagnostics and Predictive Biomarkers for MET-Targeted Therapy in NSCLC
por: Jørgensen, Jan Trøst, et al.
Publicado: (2022)

Real-world insights into patients with advanced NSCLC and MET alterations
por: Bittoni, Marisa, et al.
Publicado: (2021)

Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management
por: Veillon, Remi, et al.
Publicado: (2022)

Mosaicism in von Hippel-Lindau disease: an event important to recognize
por: Santarpia, Libero, et al.
Publicado: (2007)

Devil in the detail: MET overexpression fails as surrogate marker for MET exon 14 splice site mutations in NSCLC
por: Strickland, Matthew R., et al.
Publicado: (2020)

History of Extensive Disease Small Cell Lung Cancer Treatment: Time to Raise the Bar? A Review of the Literature
por: Lazzari, Chiara, et al.
Publicado: (2021)

Optimal Treatments for NSCLC Patients Harboring Primary or Acquired MET Amplification
por: Sun, Dantong, et al.
Publicado: (2022)

Dynamic Evaluation of Circulating miRNA Profile in EGFR-Mutated NSCLC Patients Treated with EGFR-TKIs
por: Leonetti, Alessandro, et al.
Publicado: (2021)

Selective IgA Deficiency and Allergy: A Fresh Look to an Old Story
por: Cinicola, Bianca Laura, et al.
Publicado: (2022)

Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC
por: Wang, Kaiwen, et al.
Publicado: (2023)

Comprehensive analysis of MET mutations in NSCLC patients in a real-world setting
por: Ai, Xinghao, et al.
Publicado: (2022)

MET gene amplification is a mechanism of resistance to entrectinib in ROS1+ NSCLC
por: Tyler, Logan C., et al.
Publicado: (2022)

KRAS in NSCLC: State of the Art and Future Perspectives
por: Cascetta, Priscilla, et al.
Publicado: (2022)

New Preclinical Development of a c-Met Inhibitor and Its Combined Anti-Tumor Effect in c-Met-Amplified NSCLC
por: Kim, Nam Ah, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9s1p3kv3sjddh82bj58j5vss7c